Mark Goldsmith
Mark Goldsmith is the CEO of Revolution Medicines, where he has championed the development of daraxonrasib, an experimental drug that targets specific cancer mutations and has shown promise in clinical trials.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Israel:
Mark Goldsmith, CEO of Revolution Medicines, stated that the team is working around the clock to prepare for full approval of the drug.
7
Greece:
Mark Goldsmith recalled that most scientists thought their method would destroy normal cells.
6